A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

NCT02256436 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

542

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

BIOLOGICAL: pembrolizumab
DRUG: paclitaxel
DRUG: vinflunine
DRUG: docetaxel

Sponsor

Merck Sharp & Dohme LLC